Terao Ryo, Fujino Ryosuke, Ahmed Tazbir
Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8654, Japan.
Department of Ophthalmology & Visual Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.
J Clin Med. 2022 Oct 27;11(21):6340. doi: 10.3390/jcm11216340.
Retinal occlusive diseases are common diseases that can lead to visual impairment. Retinal artery occlusion and retinal vein occlusion are included in the clinical entity, but they have quite different pathophysiologies. Retinal artery occlusion is an emergent eye disorder. Retinal artery occlusion is mainly caused by thromboembolism, which frequently occurs in conjunction with life-threatening stroke and cardiovascular diseases. Therefore, prompt examinations and interventions for systemic vascular diseases are often necessary for these patients. Retinal vein occlusion is characterized by retinal hemorrhage and ischemia, which may impair visual function via several complications such as macular edema, macular ischemia, vitreous hemorrhage, and neovascular glaucoma. Even though anti-vascular endothelial growth factor therapy is the current established first-line of treatment for retinal vein occlusion, several clinical studies have been performed to identify better treatment protocols and new therapeutic options. In this review, we summarize the current findings and advances in knowledge regarding retinal occlusive diseases, particularly focusing on recent studies, in order to provide an update for a better understanding of its pathogenesis.
视网膜阻塞性疾病是可导致视力损害的常见疾病。视网膜动脉阻塞和视网膜静脉阻塞属于这一临床范畴,但其病理生理学有很大差异。视网膜动脉阻塞是一种急性眼部疾病。视网膜动脉阻塞主要由血栓栓塞引起,常与危及生命的中风和心血管疾病同时发生。因此,对这些患者而言,往往需要对全身性血管疾病进行及时检查和干预。视网膜静脉阻塞的特征是视网膜出血和缺血,可通过黄斑水肿、黄斑缺血、玻璃体积血和新生血管性青光眼等多种并发症损害视功能。尽管抗血管内皮生长因子治疗是目前已确立的视网膜静脉阻塞一线治疗方法,但仍开展了多项临床研究以确定更好的治疗方案和新的治疗选择。在本综述中,我们总结了关于视网膜阻塞性疾病的当前研究结果和知识进展,尤其侧重于近期研究,以便提供最新信息,增进对其发病机制的了解。